cediranib + cisplatin + capecitabine

Cediranib + cisplatin + capecitabine is a combination regimen used primarily in clinical trials for advanced gastric cancer and other solid tumors. **Cediranib** is an oral small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3 tyrosine kinases, reducing tumor angiogenesis. **Cisplatin** is a platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis. **Capecitabine** is an orally-administered prodrug of fluorouracil, an antimetabolite that interferes with DNA synthesis in rapidly dividing cells. The combination targets both tumor cells (with cytotoxic agents) and tumor vasculature (with antiangiogenic therapy). Development and testing have focused on advanced and metastatic gastric cancer, showing preliminary evidence of safety and antitumor activity in early-phase studies[1][4][8].